pennystockhaven
  • Facebook
  • Twitter
  • Youtube
  • Rss
Day-Trading Penny Stocks
  • Home
  • Services
  • Contact Us
Home» Commentary » IBIO, UPIP, TELK: Plays On Biotech And Technology Markets

IBIO, UPIP, TELK: Plays On Biotech And Technology Markets

Posted on January 13, 2013 by PennyStockHaven in Commentary, Stock Market Movers & Losers

ibio logoiBio, Inc. (IBIO)

Sophisticated traders must take a look at iBio, Inc. (IBIO) as it seems that company has been overlooked as a solid player on the flu market.

The high level of flu cases being reported across all states in the USA and Europe. Only in New York state a flu epidemic has hit more than 19,000 people.

Friday’s official announcements that the flu vaccine is in short supply, in the midst of an early flu season, fired up the speculative targets for IBIO stock. Shares of IBIO jumped 29%, ended trading session at 80 cents.

more at smallcapbiotech

upip logoUnwired Planet (UPIP)

Unwired Planet announced on Friday that it has entered into a patent purchase agreement with Ericsson (ERIC).

Ericsson has agreed to transfer 1,922 patents and 263 patent applications to Unwired Planet in return for a share in ongoing revenue from the patents.

The transfer includes 753 U.S. patents related to 2G, 3G and LTE technologies.

UPIP shares jumped 42% at the end of Friday’s trading session.

Keep a close look at UPIP stock that should have a Vringo (VRNG) run-up effect judging by its relatively small float and stable financial condition.

more at smallcaptechnology

telik logoTelik, Inc. (TELK)

TELK announced on Friday that its product candidate, Telintra, has been granted orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of myelodysplastic syndrome (MDS).

TELK stock jumped 105% on Friday’s trading session, ended at $2.98 per share on 48fold of its 10day average volume.

Key points:

  • Burning rate will blow out TELK available cash in the next quarter
  • Clinical trials will require more funding at the end of Q1- or beginning of Q2 2013
  • No signifficant short interest, thus no short squeeze is expected

Summary:

Second offering is imminent. Short position in TELK is a way to go.

More at smallcapbiotech

IBIO, TELK, UPIP

Search

Real Time Alerts:

Tweets by @PennyStockHaven

Updates

  • CVR Partners, LP (NYSE: UAN): the dividend play

    February 26, 2023
  • Sotera Health

    Sotera Health Company (NASDAQ:SHC): hard road ahead

    February 21, 2023
  • ZIM Integrated Shipping Services (NYSE:ZIM) uphill movement

    February 20, 2023
  • Carvana Co. (NYSE: CVNA) way to go… down

    February 17, 2023
  • ReWalk Robotics (RWLK): Yesterday, Today and Tomorrow

    June 8, 2019
  • Amyris, Inc. (AMRS): How to Mislead Investors

    April 21, 2019
  • ADMA Biologics, Inc. (ADMA): Offering is Imminent

    April 11, 2019
  • Proteostasis Therapeutics (PTI): Market Overreaction

    March 26, 2019
  • Dynagas LNG Partners LP (NYSE: DLNG) Coming Off Of Bottom

    February 1, 2019
  • Histogenics Corporation (HSGX) market: only upside from these levels

    September 5, 2018
  • Quantum Corp. (QTM): Appointed Jamie Lerner as Chief Executive Officer and President

    June 26, 2018
  • FuelCell Energy (NASDAQ:FCEL) A picture is worth a thousand words

    June 22, 2018

    Site

    • Home
    • Services
    • Contact Us
    • About Us
    • Privacy Policy
    • Terms of Use
    • Disclaimer
    • Publishers

    Financial Network

    Yahoo Finance
    Reuters
    The Motley Fool
    WSJ
    CNBC
    Business Week
    The Street
    Bloomberg

    psh sloganYour Everything Penny Stocks Resource



    Copyright © 2021 PennyStockHaven.com. All Rights Reserved